首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Efficacy of Traditional Chinese Medicine Regimen Jian Pi Qu Shi Formula for Refractory Patients with Idiopathic Membranous Nephropathy: A Retrospective Case-Series Study
【24h】

Efficacy of Traditional Chinese Medicine Regimen Jian Pi Qu Shi Formula for Refractory Patients with Idiopathic Membranous Nephropathy: A Retrospective Case-Series Study

机译:中医养生鉴脾祛湿方对难治性特发性膜性肾病患者的回顾性病例系列研究

获取原文
       

摘要

Background. The treatment of adult refractory idiopathic membranous nephropathy with steroid and other immunosuppressant-resistant nephrotic syndromes can be a significant challenge. We evaluated the efficacy and safety of the traditional Chinese medicine Jian Pi Qu Shi Formula (JPQSF) as a promising regimen. Methods. We analyzed 15 consecutive patients with biopsy-proven idiopathic membranous nephropathy who failed immunosuppressive therapy from October 2013 to January 2017. JPQSF was administered orally two times per day, respectively, in the morning and at night for 6 months. All patients had at least 1 year of follow-up. The primary endpoints included complete or partial remission. Secondary endpoints included change of clinical parameters and adverse events after 12 months of treatment. Results. After 12 months, complete remission was achieved in 13.3% of patients and partial remission in 66.7%, yielding a response rate of 80%. Proteinuria, serum albumin, and cholesterol were improved significantly (P<0.001, P<0.001, and P<0.05, respectively). After 1 year of treatment, proteinuria (mean ± SD) decreased from 5.93 ± 2.54 g per 24 h to 1.99 ± 1.17 g per 24 h (P<0.001). No serious adverse events occurred during the observation. Conclusions. JPQSF may be an alternative therapeutic option for steroid and general immunosuppressant-resistant membranous nephrotic syndrome patients, with a favorable safety profile. Larger and longer follow-up studies evaluating this regimen are warranted.
机译:背景。用类固醇和其他抵抗免疫抑制剂的肾病综合征治疗成人难治性特发性膜性肾病可能是一项重大挑战。我们评估了中药健脾祛湿方(JPQSF)作为一种有前途的治疗方案的疗效和安全性。方法。我们分析了2013年10月至2017年1月连续15例经活检证实为特发性膜性肾病的免疫抑制治疗失败的患者。JPQSF每天口服两次,分别在早晨和晚上进行,共6个月。所有患者至少接受了一年的随访。主要终点包括完全缓解或部分缓解。次要终点包括治疗12个月后临床参数的变化和不良事件。结果。 12个月后,完全缓解的患者达到了13.3%,部分缓解的率为66.7%,缓解率为80%。蛋白尿,血清白蛋白和胆固醇显着改善(分别为P <0.001,P <0.001和P <0.05)。治疗1年后,蛋白尿(平均值±标准差)从每24h的5.93±2.54μg降至每24h的1.99±1.17μg(P <0.001)。在观察期间没有发生严重的不良事件。结论。 JPQSF可能是类固醇和一般抵抗免疫抑制剂的膜性肾病综合征患者的替代治疗选择,其安全性良好。评估该方案的更大和更长的随访研究是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号